- Else Nutrition (TSX:BABY) is announcing the first rollout of its infant formula in Australia and New Zealand
- The launch positions the company for a planned expansion of its entire product line across the more than US$50 billion Asia Pacific baby, infant and toddler food market
- Else Nutrition develops plant-based food and nutrition products for infants, toddlers, children and adults
- Else Nutrition stock has given back 65.66 per cent year-over-year and 59.29 per cent over the past five years
Else Nutrition (TSX:BABY) is announcing the first rollout of its infant formula in Australia and New Zealand, setting the stage for a planned expansion of its entire product line across the more than US$50 billion Asia Pacific baby, infant and toddler food market.
The infant formula for children 6-12 month old, as well as Else’s toddler drink for children 12-36 months old, are now available on Amazon Australia, with plans in place for them to hit shelves in brick-and-mortar locations and other online retailers in the near future.
Filling a global unmet need
Standard infant formulas tend to be ultra-processed, leading to digestive complications for certain children. This includes dairy formulas, which have been shown to contain major allergens, antibiotics and hormones, and represent about 95 per cent of the global market.
Additionally, soy protein formulas, which represent about 5 per cent of the market, can cause similar side effects because of overprocessing and high levels of phytoestrogens and GMOs.
Source: Else Nutrition
In contrast, Else’s new infant formula – composed primarily of almonds, buckwheat and tapioca – is modelled on human-milk nutritional gold standards, including ratio standards for amino acids, fatty acids and macronutrients, offering essential nutrition for growth and development as a child transitions to solid foods.
The formula further addresses parents’ concerns by requiring no chemical processing, keeping proteins intact, and containing no antibiotics, hormones, pesticides, GMOs or heavy metals, while being up to 65 per cent more carbon-efficient than dairy and soy-based products.
Management insights
“We are extremely proud to officially launch our infant formula and our toddler drink in Australia, serving as a beachhead for the planned global expansion of our range of breakthrough products,” Hamutal Yitzhak, Else Nutrition’s co-founder and chief executive officer, said in a statement.
“We selected Australia after a meticulous evaluation of the regulatory framework and were deemed in compliance. Australia is widely recognized for its rigorous health and other regulatory standards. In addition, Australia is strategically located in the Asia Pacific region, which we envision will be an ideal market from which to expand our other line of products across the region. The Asia Pacific region represents an extremely large addressable market, desiring safe and high-quality Western products, especially in the children’s health and nutrition categories. Our strategic focus is on establishing partnerships in this region to support our expansion efforts.”
“We are delighted to work with Amazon in Australia and look forward to expanding our footprint through additional retail and online distribution channels, as we have demonstrated in North America. We are on a mission to revolutionize infant and toddler nutrition by providing products that meet the needs of families seeking clean-label alternatives based on dairy and soy-free, whole-plant, minimally processed ingredients,” Yitzhak said.
About Else Nutrition
Else Nutrition Holdings develops plant-based food and nutrition products for infants, toddlers, children and adults.
Else Nutrition stock (TSX:BABY) last traded at C$0.285 per share. The stock has given back 65.66 per cent year-over-year and 59.29 per cent over the past five years.
Join the discussion: Learn what other investors are saying about the company’s infant formula and its Australian launch on the Else Nutrition Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.